| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 23 | 2025 | 2648 | 2.610 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2025 | 816 | 1.350 |
Why?
|
| Trastuzumab | 9 | 2025 | 147 | 0.960 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 1325 | 0.870 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2011 | 26 | 0.800 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 125 | 0.790 |
Why?
|
| NF-kappa B | 6 | 2011 | 449 | 0.780 |
Why?
|
| Curcumin | 3 | 2011 | 43 | 0.750 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 2021 | 0.700 |
Why?
|
| Azadirachta | 2 | 2011 | 3 | 0.700 |
Why?
|
| Signal Transduction | 16 | 2025 | 4675 | 0.680 |
Why?
|
| Estrogen Receptor alpha | 5 | 2025 | 432 | 0.640 |
Why?
|
| Plant Extracts | 2 | 2011 | 137 | 0.620 |
Why?
|
| Apoptosis | 6 | 2019 | 1854 | 0.570 |
Why?
|
| Neuroblastoma | 4 | 2011 | 557 | 0.570 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 401 | 0.520 |
Why?
|
| Gamma Rays | 3 | 2011 | 42 | 0.500 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1794 | 0.500 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2025 | 619 | 0.500 |
Why?
|
| Gene Fusion | 1 | 2016 | 60 | 0.480 |
Why?
|
| Biomarkers, Tumor | 7 | 2023 | 1607 | 0.460 |
Why?
|
| Radiation, Ionizing | 2 | 2011 | 39 | 0.420 |
Why?
|
| Carrier Proteins | 2 | 2020 | 1018 | 0.410 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2025 | 82 | 0.400 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 3703 | 0.390 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 328 | 0.370 |
Why?
|
| Rosaceae | 1 | 2011 | 1 | 0.360 |
Why?
|
| Molecular Targeted Therapy | 4 | 2025 | 385 | 0.350 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 54 | 0.350 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 102 | 0.340 |
Why?
|
| Quinazolines | 3 | 2023 | 181 | 0.340 |
Why?
|
| Mice, Nude | 5 | 2025 | 708 | 0.330 |
Why?
|
| Digestive System | 1 | 2010 | 61 | 0.330 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 179 | 0.330 |
Why?
|
| Genes, p53 | 1 | 2010 | 211 | 0.310 |
Why?
|
| Receptors, Estrogen | 5 | 2021 | 731 | 0.300 |
Why?
|
| Sarcoma, Ewing | 1 | 2010 | 117 | 0.300 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 1844 | 0.290 |
Why?
|
| Gene Amplification | 3 | 2019 | 226 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 642 | 0.280 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 245 | 0.280 |
Why?
|
| Genomics | 1 | 2016 | 1623 | 0.270 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 691 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 345 | 0.250 |
Why?
|
| Female | 23 | 2025 | 70670 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 744 | 0.230 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 58 | 0.220 |
Why?
|
| Protein Kinases | 2 | 2016 | 317 | 0.220 |
Why?
|
| Humans | 30 | 2025 | 130842 | 0.220 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 358 | 0.210 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2025 | 157 | 0.210 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2011 | 62 | 0.190 |
Why?
|
| Cell Survival | 4 | 2021 | 840 | 0.190 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 301 | 0.190 |
Why?
|
| Prognosis | 5 | 2021 | 4934 | 0.180 |
Why?
|
| Carcinogenesis | 1 | 2025 | 351 | 0.180 |
Why?
|
| Mice | 10 | 2025 | 18246 | 0.180 |
Why?
|
| Remission Induction | 2 | 2020 | 301 | 0.180 |
Why?
|
| Linear Energy Transfer | 2 | 2011 | 9 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 1307 | 0.170 |
Why?
|
| Plant Leaves | 2 | 2011 | 56 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 49 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 65 | 0.160 |
Why?
|
| Pyrimidinones | 1 | 2020 | 64 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 996 | 0.160 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 20 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 224 | 0.150 |
Why?
|
| Pyridones | 1 | 2020 | 149 | 0.150 |
Why?
|
| Pyridines | 1 | 2021 | 258 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 252 | 0.150 |
Why?
|
| Piperazines | 1 | 2021 | 270 | 0.150 |
Why?
|
| Cinnamates | 1 | 2018 | 16 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 144 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 89 | 0.140 |
Why?
|
| Brain | 1 | 2010 | 3224 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2019 | 347 | 0.140 |
Why?
|
| Animals | 10 | 2025 | 33938 | 0.140 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 3 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 752 | 0.130 |
Why?
|
| Indoles | 1 | 2018 | 201 | 0.130 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 1382 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 545 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2019 | 381 | 0.120 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 663 | 0.120 |
Why?
|
| Gene Expression | 1 | 2020 | 1488 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 963 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2016 | 246 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 479 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 106 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2018 | 2477 | 0.100 |
Why?
|
| Open Reading Frames | 1 | 2014 | 199 | 0.100 |
Why?
|
| Cell Separation | 1 | 2014 | 220 | 0.100 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 61 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1623 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5230 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 291 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1950 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 632 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2023 | 12912 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2011 | 3 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2014 | 770 | 0.090 |
Why?
|
| Aminoquinolines | 1 | 2011 | 36 | 0.090 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 11 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2011 | 21 | 0.090 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2011 | 33 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2011 | 37 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1307 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 418 | 0.090 |
Why?
|
| Time Factors | 2 | 2011 | 6243 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 916 | 0.080 |
Why?
|
| Infrared Rays | 1 | 2010 | 20 | 0.080 |
Why?
|
| Cell Movement | 1 | 2014 | 872 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 66 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1729 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 623 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2011 | 295 | 0.080 |
Why?
|
| Fruit | 1 | 2011 | 235 | 0.080 |
Why?
|
| Telomerase | 1 | 2011 | 155 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 172 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 604 | 0.080 |
Why?
|
| Transfection | 1 | 2011 | 947 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 417 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1218 | 0.070 |
Why?
|
| Phenotype | 2 | 2016 | 4483 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2020 | 351 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2011 | 2558 | 0.070 |
Why?
|
| Mutation | 3 | 2025 | 6150 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 209 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1457 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1236 | 0.060 |
Why?
|
| Base Sequence | 1 | 2010 | 2746 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2021 | 1571 | 0.060 |
Why?
|
| DNA | 1 | 2011 | 1412 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 756 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 803 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2025 | 38 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1392 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3417 | 0.060 |
Why?
|
| Laminin | 1 | 2025 | 68 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 567 | 0.050 |
Why?
|
| Cytokines | 1 | 2009 | 1339 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 988 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2016 | 829 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4709 | 0.040 |
Why?
|
| Middle Aged | 4 | 2025 | 28510 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 89 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 103 | 0.040 |
Why?
|
| Dasatinib | 1 | 2020 | 53 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2020 | 92 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 76 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 85 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 378 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 216 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 306 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 178 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2009 | 136 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 393 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 192 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 8 | 0.030 |
Why?
|
| Estradiol | 1 | 2018 | 477 | 0.030 |
Why?
|
| Estrogens | 1 | 2018 | 432 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1512 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 230 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 162 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 595 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1007 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 519 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2935 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 57 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 20968 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 235 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 284 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4669 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 1323 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1679 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 11 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 42 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 31274 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6784 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 249 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 674 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 1213 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 363 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 10025 | 0.010 |
Why?
|